Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03174054
Overview
Prostate cancer is a common disease in men. In prostate 35% of biopsies, usually done due to increased PSA levels or clinical suspicion, are false negative, despite malignancy. Multi-parametric prostate MRI detects malignant neoplasm lesions better than other imaging devices. A sonar-guided prostate biopsy based on multi-parametric MRI images improves detection of malignancy. Ga68 PSMA-PET test uses a radioactive marker that binds to the prostate's cells and is shown to be a primary prostate tumor site in addition to metastasis. We believe that the combination of measures from a single Ga68 PSMA and multi-parametric MRI test can lead to further improvement in malignancy, better biopsy guidance, and optimal treatment for the patient.
Sponsor
Samsung Medical Center
Contacts
David Groshar, MD (CONTACT)
davidg@assuta.co.il
+972-37645497
David Groshar, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03174054Drug / Compound
Eligibility
Help us improve your experience